NextEvo Naturals recently released results from a third-party study on 16 CBD products that were allegedly randomly selected for the research. The brand commissioned Coral Reef Labs to conduct this study and test label claims including the potency of each product. In this study, one of CV Sciences’ (OTCQB: CVSI) products was “randomly” chosen and found to fail the test, reporting that its potency was 9mg of CBD rather than the 10mg claimed on the label.
The company quickly issued a commentary on the study, questioning the veracity of the report.
“There are a variety of issues with this study and the debasing claims against CV Sciences’ products. To start, NextEvo claims to have randomly selected 16 CBD products from the shelves of randomly selected grocery store and supplement store chains in Eastern Pennsylvania, conveniently choosing selections from some of the leading brands on the market, including one from CV Sciences and two from Charlotte’s Web (OTCQX: CWBHF), two of which ‘failed’ the test while all three NextEvo products ‘passed,’” the company said.
What About Certification?
CV Sciences further called into question the credibility of the new testing laboratory – Coral Reef Labs, claiming it lacks “commonly recognized ISO-17025 certification that enables laboratories to show they operate competently and generate valid, reliable results. Thanks to a lack of standardized regulations across the board, methods in testing can be highly variable…
MMP News Author
Source link
